Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial

European Journal of Heart Failure

Volumn 11, Issue 10, 2009, Pages 990-999

  Zick, Suzanna M ^a   Vautaw, Bonnie Motyka ^b,c   Gillespie, Brenda ^b   Aaronson, Keith D ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c FORD MOTOR COMPANY   (United States)

Author keywords

Crataegus; Hawthorn; Heart failure; Systolic

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CRATAEGUS EXTRACT; CRATEGUTT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; NEUROHORMONE; PLACEBO; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG ERUPTION; DRUG TOLERABILITY; EXERCISE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; ANAEROBIC THRESHOLD; CHRONIC DISEASE; CRATAEGUS; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; OXYGEN CONSUMPTION; PHYTOTHERAPY; PLANT PREPARATIONS; PROBABILITY; QUALITY OF LIFE; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 70349659932     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hfp116     Document Type: Article

References (30)

1. Weihmayr T, Ernst E. Therapeutic effectiveness of Crataegus. Fortschr Med 1996; 114:27-29.
2. Garjani A, Nazemiyeh H, Maleki N, Valizadeh H. Effects of extracts from flowering tops of Crataegus meyeri A. Pojark. on ischaemic arrhythmias in anaesthetized rats. Phytother Res 2000;14:428-431.
3. Chatterjee SS, Koch E, Jaggy H, Krzeminski T. In vitro and in vivo studies on the cardioprotective action of oligomeric procyanidins in a Crataegus extract of leaves and blooms. Arzneimittel-Forschung 1997;47:821-825.
4. Occhiuto F, Circosta C, Briguglio F, Tommasini A, de Pasquale A. Comparative study of the cardiovascular activity of shoots, leaves and flowers of Crataegus oxyacantha: 1. Electrical activity and arterial pressure in the rat. Plantes medicinales et phytotherapie 1986;20:37-51.
5. Occhiuto F, Circosta C, Costa R, Briguglio F, Tommasini A. Comparative study of the cardiovascular activity of shoots, leaves and flowers of Crataegus oxyacantha: 2. Action of extracts and isolated pure active principles on the isolated rabbit heart. Plantes medicinales et phytotherapie 1986;20:52-63. (Pubitemid 16029847)
6. Brixius K, Frank K, Munch G, Muller-Ehmsen J, Schwinger RHG. WS 1442 (Crataegus-Special Extract) increases contractile force in the myocardium of humans with congestive heart failure. Herz-Kreislauf 1998;30:28-33.
7. Ruchstuhl M, Beretz A, Anton R, Landry Y. Flavonoids are selective cyclic GMP phosphodiesterase inhibitors. Biochem Pharmacol 1979;28:535-538.
8. Schussler M, Holzl J, Fricke U. Myocardial effects of flavonoids from Crataegus species. Arzneimittelforschung 1995;45:842-845.
9. Periera da Silva A, Rocha R, Silva CM, Mira L, Duarte MF, Florencio MH. Antioxidants in medicinal plant extracts. A research study of the antioxidant capacity of Crataegus, Hamamelis and Hydrastis. Phytother Res 2000;14:612-616.
10. Bahorun T, Aumjaud E, Ramphul H, Rycha M, Luximon-Ramma A, Trotin F, Aruoma OI. Phenolic constituents and antioxidant capacities of Crataegus monogyna (Hawthorn) callus extracts. Nahrung 2003;47:191-198.
11. Masquelier J. Pycnogenols: recent advances in the therapeutical activity of procyanidins. Beal JL, Reinhard E (eds), Natural Products as Medicinal Agents: Plenary Lectures of the International Research Congress on Medicinal Plant Research, Stuttgart, July 1980. Strasbourg, Hippokrates Verlag; 1981.
12. Pittler MH, Schmidt K, Ernst E. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. Am J Med 2003;114:665-674.
13. Zick SM, Gillespie B, Aaronson KD. The effect of Crataegus oxycantha Special Extract WS 1442 on clinical progression in patients with mild to moderate symptoms of heart failure. Eur J Heart Fail 2008;10:587-593.
14. Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997;95: 2660-2667.
15. Group TE. EuroQoL-A new facility for the measurement of health related quality of life. Health Policy 1990;16:199-208.
16. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE trial. Circulation 1996;94:2793-2799.
17. Leuchtgens H. Crataegus Special Extract WS 1442 in NYHA II heart failure. A placebo controlled randomized double-blind study. Fortschr Med 1993;111: 352-354.
18. O'Connolly M, JansenW, Bernhoft G, Bartsch G. Treatment of decreasing cardiac performance. Therapy using standardized Crataegus extract in advanced age. Fortschritte der Medizin 1986;104:805-808.
19. Hanack T, Bruckel MH. The treatment of mild stable forms of angina pectoris using Crategutt novo. Therapiewoche 1983;33:4331-4333.
20. Zapfe G. Clinical efficacy of Crataegus Extract WS 1442 in congestive heart failure NYHA Class II. Phytomedicine 2001;8:262-266.
21. Bodigheimer K, Chasa D. Effectiveness of hawthorn extract at a dosage of 3 100 mg per day. Multicentre double-blind trial with 85 NYHA stage II heart failure patients. Munch Med Wschr 1994;136:S7-S11.
22. Weikl A, Assmus KD, Neukum-Schmidt A, Schmitz J, Zapfe G, Noh HS, Siegrist J. Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II). Fortschr Med 1996;114: 291-296.
23. O'Connolly VM, Jansen W, Bernhoft G, Bartsch G. Treatment of heart failure. Fortschr Med 1986;104:805-808.
24. Tauchert M. Efficacy and safety of Crataegus Extract WS 1442 in comparison with placebo in patients with chronic stable New York Heart Association Class-III heart failure. Am Heart J 2002;143:910-915.
25. Tauchert M, Ploch M, Hubner W-D. Effectiveness of the hawthorn extract LI 132 compared with the ACE inhibitor captopril. Multicentre double-blind study with 132 NYHA stage II heart failure patients. Munchener Medizinische Wochenschrift 1994;136:S27-S33. (Pubitemid 24077617)
26. Strauss P, Ietta M, Thomas S, Fichman B. The mean blood pressure-heart rate quotient and systolic blood pressure-heart rate product are not useful indicators of myocardial ischemia. Anesthesiology 1989;71
27. Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, Kronenberg MW, Kostis JB, Kohn RM, Guillotte M. Prediction of mortality and morbidity with a 6 min walk test in patients with left ventricular dysfunction. JAMA 1993;270:1702-1707.
28. Demers C, McKelvie R, Negassa A, Yusuf S. RESOLVD Pilot Study Investigators. Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. Am Heart J 2001;142:698-703.
29. Mancini DM, Eisen H, KussmaulW, Mull R, Edmunds LH, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991;83:778-786.
30. Holubarsch C, Colucci W, Meinertz T, Gaus W, Tendera M. Crataegus extract WSw 1442, congestive heart failure, survival, efficacy, safety, controlled randomized trial. Eur J Heart Failure 2008;10:1255-1263.